Cosmos Holdings

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Chicago, IL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

Provides Additional Financial Flexibility in Exchange for New Warrants CHICAGO, IL / ACCESSWIRE / October 4, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("Cosmos") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into an agreement to replace its previously structured warrants with new vanilla warrants. The existing holders of Warrants issued as of February 28, 2022 will purchase an aggregate of 21,238,254 shares of Common Stock.

Cosmos Health Enters into a Warrant Exchange Agreement, Replacing Structured Warrants with Plain-Vanilla Warrants

CHICAGO, IL / ACCESSWIRE / September 22, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("Cosmos") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits. Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis.

Cosmos Health Signs an Agreement with Virax Biolabs to Distribute Monkeypox Virus Real-Time PCR Detections Kits in Europe

Virax Biolabs Group Ltd

Exclusive distribution agreement signed with Cosmos Holdings Inc. (Nasdaq: COSM), providing for exclusive distribution rights in Greece and Cyrus with the opportunity for Cosmos to distribute across Europe on a non-exclusive basis. LONDON , Sept.

Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

CHICAGO, IL / ACCESSWIRE / September 15, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , is a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that the Company's proprietary line of nutraceuticals, Sky Premium Life, has entered into an exclusive agreement with Mediprovita GbR. Mediprovita will begin selling its Sky Premium Life ("SPL") products in Germany and Austria beginning in the Fourth Quarter.

Cosmos Health to Launch Sky Premium Life Nutritional Supplement Products in Germany and Austria via Amazon and Ebay

CHICAGO, IL / ACCESSWIRE / August 25, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("the Company") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that the Company's subsidiary, SkyPharm S.A., a pharmaceutical wholesaler and distributor, officially launched its first Sky Premium Life ("SPL") products on Amazon in the United States.

Cosmos Health Launches First Sky Premium Life Nutritional Supplement Products on Amazon in the United States

CHICAGO, IL / ACCESSWIRE / August 22, 2022 / Cosmos Health, Inc. ("the Company") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices,today provided a business update and reported financial results for the second quarter and six months ended June 30, 2022. Greg Siokas, Chief Executive Officer of Cosmos Health, stated, "We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021.

Cosmos Health Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022

CHICAGO, IL / ACCESSWIRE / July 29, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) announced today that it is changing the name of the Company to Cosmos Healthto better reflect the Company's evolution into an innovative global healthcare group with a focus on improving people's lives. The enhancement with cutting edge technlogies for the development of its pharmaceutical and nutraceutical products, through its vertical integrated ecosystem, will enable Cosmos Health to implement its goal of becoming a global healthcare group, committed to human health needs.

Cosmos Holdings Announces Name Change to Cosmos Health, Reflecting Company's Evolution into an Innovative Global Healthcare Group, Driven by One Purpose: Improving People's Lives

Aphria

CHICAGO, IL / ACCESSWIRE / July 22 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has appointed finance veteran Dr. Manfred Ziegler to the Company's Advisory Board. Dr. Ziegler brings over 30 years of executive management, financial, and operational experience, as well as extensive expertise in mergers and acquisitions, with a particular focus on high-growth public and private companies.

Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board

Cosmos Holdings, Inc. (NASDAQ: COSM) announced it is buying Cana. This is why.

Why Cosmos Holdings (COSM) Is Buying Cana

CHICAGO, IL / ACCESSWIRE / July 20, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has entered into a binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A. , ("Cana") a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

Cosmos Holdings Announces Agreement to Acquire Cana Laboratories, a Legacy European Pharmaceutical Company Established in 1928; Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipeline with New Brands

Products will be listed on PAGB's OTC Directory online, a go-to resource for healthcare professionals CHICAGO, IL / ACCESSWIRE / July 12, 2022 / Cosmos Holdings, Inc. ("the Company") (Nasdaq:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced the Company's subsidiary, Decahedron Ltd., a UK-based pharmaceutical wholesaler, distributor and fulfillment center, has been granted full membership to the PAGB, a consumer healthcare association, that represents the manufacturers of branded OTC medicines, self-care medical devices and food supplements in the UK.

Cosmos Holdings Subsidiary Granted Full Membership in PAGB, A UK-based Consumer Healthcare Association

CHICAGO, IL / ACCESSWIRE / July 8, 2022 / Cosmos Holdings, Inc. ("the Company") (Nasdaq:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced the appointment of Panagiotis Zoumpoulakis, Ph.D., MBA, to its Advisory Board.

Cosmos Holdings Appoints Dr. Panagiotis Zoumpoulakis to its Advisory Board

Acquisition will include all launched and under development bone health products CHICAGO, IL / ACCESSWIRE / July 6, 2022 / Cosmos Holdings, Inc. ("the Company") (Nasdaq:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has entered into an agreement to acquire LIFE NLB, Ltd.'s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome.

Cosmos Holdings to Acquire LIFE NLB Portfolio of Bone Health Products that Target the Gastrointestinal Microbiome

CHICAGO, IL / ACCESSWIRE / June 30, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced a strategic partnership with Cloudpharm P.C., a bio-pharmaceutical R&D company focused on the discovery of bioactive compounds with an emphasis on natural products, with the aim of developing new medicines, cosmetics and nutraceuticals.

Cosmos Holdings Announces Strategic R&D Partnership with Cloudpharm P.C. to Study the Human Gastrointestinal Microbiome and Launch Related Products Targeting on Obesity and Other Gut-Related Disorders

First commercial launch of the Company's nutraceutical products in the U.S. follows successful launches on Amazon in other key markets CHICAGO, IL / ACCESSWIRE / June 2 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that the Company's subsidiary, SkyPharm S.A., a pharmaceutical wholesaler and distributor, is launching Sky Premium Life products on Amazon in the United States.

Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon in the United States

Reports Positive Net Income of $0.2 Million and $1.2 Million of EBITDA for the First Quarter of 2022 CHICAGO, IL / ACCESSWIRE / May 18, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, "I am pleased to report revenue increased 12.5% to $13.1 million, gross profit increased 88.9% to $1.89 million and we achieved profitability for the first quarter of 2022.

Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022

First commercial launch of nutraceutical products in North American Market CHICAGO, IL / ACCESSWIRE / May 5, 2022 / Cosmos Holdings, Inc. ("the Company") (Nasdaq:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that the Company's subsidiary, SkyPharm S.A., a pharmaceutical wholesaler and distributor, is launching Sky Premium Life products on Amazon Canada.

Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon Canada

Euroseas

CHICAGO, IL / ACCESSWIRE / May 3, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced it has appointed finance veteran Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board's audit committee. Dr. Anastasios Aslidis currently serves as the Chief Financial Officer and Treasurer, as well as a member of the Board of Directors of EuroDry (EDRY) since 2018.

Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board's Audit Committee

Cosmos Holdings (COSM) stock is seeing major gains on Wednesday with heavy trading despite a lack of recent news from the company. The post COSM Stock Alert: 7 Things to Know About Red-Hot Cosmos Holdings appeared first on InvestorPlace.

COSM Stock Alert: 7 Things to Know About Red-Hot Cosmos Holdings

Acutus Medical

Kintara Therapeutics

Here's what you need to know about trading penny stocks on April 27th The post Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading

CHICAGO, IL / ACCESSWIRE / April 19, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update and reported financial results for the year ended December 31, 2021. Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, "We are pleased to have another year of revenue growth, as well as positive adjusted net income and positive adjusted EBITDA (as defined below) for the year ended December 30, 2021.

Cosmos Holdings Reports Continued Revenue Growth and Achieves $3.3 Million of Adjusted EBITDA for the Fiscal Year 2021

New line contains unique formulations and ingredients found in specific regions in Greece and the Mediterranean CHICAGO, IL / ACCESSWIRE / April 12, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced thatSky Premium Life, Cosmos' proprietary luxury nutritional supplement product line, has launched Mediterranation, a new premium line of nutritional supplements. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean.

Cosmos Holdings Launches Mediterranation, a New Premium Nutritional Supplements Line

CHICAGO, IL / ACCESSWIRE / April 5, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that the Company's subsidiary, SkyPharm S.A., a pharmaceutical wholesaler and distributor, is launching Sky Premium Life products on Amazon Singapore.

Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon Singapore

Designed to support and enhance brain function CHICAGO, IL / ACCESSWIRE / March 31, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, announced today that Sky Premium Life, Cosmos' proprietary luxury nutritional supplement product line, has launched Brainlit for brain health. Cosmos' R&D team has developed an advanced formula that is designed to support and enhance brain function.

Cosmos Holdings Launches Proprietary Sky Premium Life Brainlit Supplement for Brain Health

Designed to prevent and protect against Benign Prostate Hyperplasia, which affects millions of men worldwide CHICAGO, IL / ACCESSWIRE / March 28, 2022 / Cosmos Holdings, Inc. ("the Company") (Nasdaq:COSM) , an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, announced today that Sky Premium Life, Cosmos' proprietary luxury nutritional supplement product line, has launched Prostatium for prostate health. This innovative formula is designed to boost prostate health, as well as alleviate and prevent Benign Prostate Hyperplasia (BPH) symptoms.

News for Cosmos Holdings Stock (COSM)